Reliable. Secure. Since 2012. Exchange Crypto Sign up to get a trading fee discount!
Neovascular Age-Related Macular Degeneration (nAMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com
Neovascular age-related macular degeneration (nAMD) represents one of the leading causes of blindness globally, with its prevalence projected to rise in conjunction with the aging population in various countries. The pathogenesis of nAMD is characterized by abnormal angiogenesis and macular neovascularization (MNV), also referred to as choroidal neovascularization (CNV), along with vascular leakage, hemorrhage, and scarring, which collectively contribute to irreversible vision loss. Various mediators are implicated in this multifaceted process, including kinases, cytokines, and growth factors, with the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) being the most prominent. The advent of anti-VEGF agents, such as ranibizumab, bevacizumab, aflibercept, brolucizumab, and faricimab, has significantly transformed the clinical management of nAMD. However, an unmet clinical need persists for novel and enhanced therapies, as many patients exhibit suboptimal responses, experience a loss of efficacy over time, or require more durable treatment options, which affects real-world outcomes.
• It is estimated that approximately 1 in 10 individuals with any signs of age-related macular degeneration (AMD) will develop nAMD.
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neovascular Age-Related Macular Degeneration (nAMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Neovascular Age-Related Macular Degeneration (nAMD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Neovascular Age-Related Macular Degeneration (nAMD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Neovascular Age-Related Macular Degeneration (nAMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033